Rockefeller Capital Management
SNDX icon

Rockefeller Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Rockefeller Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.1K Hold
3,209
– – ﹤0.01% 3180
2026
Q1 		$75K Buy
3,209
+2,737
+580% +$59.5K ﹤0.01% 3032
2025
Q4 		$9.92K Buy
+472
New +$8.23K ﹤0.01% 3802
2023
Q1 		– Sell
-113
Closed -$2K – 3627
2022
Q4 		$2K Hold
113
– – ﹤0.01% 3606
2022
Q3 		$2K Hold
113
– – ﹤0.01% 3628
2022
Q2 		$2K Buy
+113
New +$1.88K ﹤0.01% 3828

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Rockefeller Capital Management's SNDX Position: Q2 2026 in Review

Rockefeller Capital Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 3,209 shares worth $70.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3180.

Rockefeller Capital Management first reported a position in SNDX in Q2 2022 and has held it in 6 quarters since. The position peaked at $75K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Rockefeller Capital Management held 3,209 shares of Syndax Pharmaceuticals worth $70.1K as of Q2 2026.
  • Rockefeller Capital Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3180 holding.
  • Rockefeller Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
  • Rockefeller Capital Management's Syndax Pharmaceuticals position peaked at $75K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.